Abstract 1590P
Background
International studies have highlighted the poor outcomes associated with cancer diagnosis following an emergency presentation (EP) to hospital. This study aims at assessing the rate of cancer patients newly referred to the Greater Paris University Hospitals (APHP) after an EP and the impact of EP on patient survival across various types of cancer.
Methods
A retrospective multicenter cohort study was conducted using the data warehouse of APHP. Consecutive patients newly referred with breast, lung, colon, rectum or pancreatic cancer between January 2019 and June 2022 were identified using claims data (ICD-10 codes). Comparative analyses between EP (diagnosis confirmed ≤30 days after emergency admission) and non-EP patients comprised in-hospital imaging, initial tumor staging from baseline PET/CT and CT-scan reports, and surgical treatment. Multivariable logistic regression was used to assess EP prevalence and its association with patient survival, adjusting for age, gender, diagnostic year (considering potential impacts of the COVID-19 pandemic), and cancer site. A Cox model was used to assess association of EP with survival, adjusting for the same factors and baseline metastatic status.
Results
The final cohort comprised 25,845 patients with 3,960 (15.3%) newly referred after an EP. EP patients exhibited higher rates of metastatic cancer (59% vs. 45%) and in-hospital imaging (53% vs. 31%), lower surgery rates (except for colon cancer patients) (18% vs 41%), and a higher risk to die within a year of diagnosis (49% vs 16%). Lung and pancreatic cancers were more frequent in EP than other cancer sites (20% and 23% respectively). The proportion of EP and non-EP patients was comparable during and after the COVID-19 pandemic, except for lung cancer. In the multivariable analysis, EP was strongly associated with age only for patients above 80 years of age (odds ratio: 3.1, 95% CI; 2.6-3.6). After adjusting for age and cancer site, patient mortality rate increased with EP referral (HR: 2.7, 95% CI 2.5-2.8).
Conclusions
Emergency presentation in a university hospital is a marker of poor outcome among newly referred cancer patients. Better coordination between hospitals and ambulatory health care networks is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1501P - Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Presenter: Luca Tontini
Session: Poster session 10
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10